Kamada (KMDA) vs Ovid Therapeutics (OVID)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Ovid Therapeutics (OVID) has outperformed Kamada (KMDA) over the past year, gaining 48.1% versus a gain of 13.7%. Over five years, KMDA leads with a +47.5% price change compared with -34.4% for OVID. Ovid Therapeutics is the larger company by market cap ($457.0 million vs $448.7 million), about 1.0 times the size.
Kamada pays a dividend yielding 3.22%, while Ovid Therapeutics does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KMDA | OVID |
|---|---|---|
| Share price | $7.78 | $2.34 |
| Market cap | $448.70M | $457.00M |
| 1-day change | -1.46% | -0.85% |
| YTD return | +10.13% | +43.56% |
| 1-year return | +13.67% | +48.10% |
| 5-year return | +47.53% | -34.44% |
| P/E ratio (TTM) | 20.46 | — |
| Forward P/E | 13.48 | — |
| EPS (TTM) | $0.38 | $-0.22 |
| Dividend yield | 3.22% | 0.00% |
| Annual dividend | $0.25 | $0.00 |
| 52-week high | $9.35 | $3.11 |
| 52-week low | $6.55 | $1.18 |
| Distance from 52-week high | -16.84% | -24.64% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +73.63% | +157.26% |
| Average volume | 118.61K | 1.57M |
| Shares outstanding | 57.71M | 195.30M |
| Employees | 462 | 23 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OVID has outperformed KMDA by 34.4 percentage points over the past year.
- Kamada offers a meaningfully higher dividend yield (3.22% vs 0.00%).
About Kamada
KMDA stock →Kamada Ltd. manufactures and sells plasma-derived protein therapeutics.
Health Care · Biotechnology: Pharmaceutical Preparations · 462 employees
About Ovid Therapeutics
OVID stock →Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia.
Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees
KMDA vs OVID FAQ
Which is bigger, Kamada or Ovid Therapeutics?
Ovid Therapeutics (OVID) is larger, with a market capitalization of $457.00M compared with $448.70M for Kamada (KMDA).
Which stock has performed better over the past year, KMDA or OVID?
OVID returned +48.10% over the past 12 months, compared with +13.67% for KMDA (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Kamada or Ovid Therapeutics?
Kamada pays a dividend yielding 3.22%, while Ovid Therapeutics does not currently pay a regular dividend.
Are Kamada and Ovid Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.